Venture funding back on track as China’s investors recalibrate

After nearly grinding to a halt in the first two months of 2020, venture money has begun to flow to China’s biotechs as investors adjust to investing amid the COVID-19 outbreak.

A spate of venture deals to kick off the month of March signaled that investors were ready to open their pocketbooks; however, companies seeking to court the country’s investors may find themselves struggling to win over new investors as they work to gain their trust in virtual meetings...